Investigational drugs for treating psoriatic arthritis.

about

New pharmacotherapy options for noninfectious posterior uveitis.Pharmacogenomics of multifactorial diseases: a focus on psoriatic arthritis.Treatment of psoriatic arthritis with traditional DMARD's and novel therapies: approaches and recommendations.

P2860

Q38253095-3825B60B-5563-418E-A2F9-3EF814C6C75C Q38857254-A29A82A7-A7CC-4D3E-B5F1-671D588AAC56 Q39003610-02630543-40D2-449B-B26D-E636CEBEEB76

P2860

Investigational drugs for treating psoriatic arthritis.

Item

http://www.wikidata.org/entity/Q38206551

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Investigational drugs for treating psoriatic arthritis.

@en

type

Item

label

Investigational drugs for treating psoriatic arthritis.

@en

prefLabel

Investigational drugs for treating psoriatic arthritis.

@en

P1476

Investigational drugs for treating psoriatic arthritis.

@en

P2093

Barry J Sheane

http://www.w3.org/2001/XMLSchema#string

Vinod Chandran

http://www.w3.org/2001/XMLSchema#string

P2860

New developments in the management of psoriasis and psoriatic arthritis: a focus on apremilast

Janus kinases in immune cell signaling

Putting together the psoriasis puzzle: an update on developing targeted therapies

Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis

Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic dr

Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial

Development, cytokine profile and function of human interleukin 17-producing helper T cells

IL-17 family cytokines and the expanding diversity of effector T cell lineages

Identification of 15 new psoriasis susceptibility loci highlights the role of innate immunity.

Treatment of plaque-type psoriasis with oral CF101: data from an exploratory randomized phase 2 clinical trial.

P304

1001-1016

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/13543784.2014.910194

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2014-04-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24758276

http://www.w3.org/2001/XMLSchema#string

Investigational drugs for treating psoriatic arthritis.

about

P2860

P2860

Investigational drugs for treating psoriatic arthritis.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698